NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Introduction
The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with forecasts of over 656,000 new cases in 2019. Collectively the drugs profiled in this report for breast and ovarian cancer are forecast to achieve almost $3.0 billion in sales in the seven major pharmaceutical markets in 2019.
Scope of this research
Examination of the breast and ovarian cancer pipelines with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions Segmentation and analysis of the current breast and ovarian cancer pipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer markets including commercial opportunity, epidemiology and discussion of unmet needs Research and analysis Highlights
There are currently 94 drugs in clinical development for breast cancer, of which 8 are in late phase development (preregistration, Phase III or pivotal Phase II trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.
There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.
R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.
Key
Reasons to Purchase this research
Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products
TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
About Datamonitor Healthcare 2
About the Oncology pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
Datamonitor insight into the breast, ovarian, and cervical cancer markets 3
Contributing experts 4
Related reports 5
Upcoming reports 5
1. Pipeline Overview and Dynamics 9
Key findings 9
Pipeline summary: breast cancer 10
Pipeline summary: ovarian cancer 13
Pipeline summary: cervical cancer 16
2. R&D Approach 17
Key findings 17
Clinical trial design in cancer 17
3. Epidemiology 21
Introduction 21
Key points 21
Epidemiologic forecasting of breast, ovarian, and cervical cancers 23
Epidemiologic results: breast cancer 27
Epidemiologic results: ovarian cancer 35
Epidemiologic results: cervical cancer 39
Strengths of Datamonitor's epidemiologic projections 44
Conclusions 44
4. Market Overview: Breast Cancer 45
Disease definition 45
Patient segmentation 46
Current treatment options 50
Unmet needs in breast cancer 56
Target product profile versus current level of attainment 59
5. Pipeline Analysis and Forecasts: Breast Cancer 61
Afatinib (BIBW-2992; Boehringer Ingelheim) 67
Afinitor (everolimus; Novartis) 72
Halaven (eribulin mesylate; Eisai) 81
Iniparib (BSI-201; BiPar Sciences/Sanofi-Aventis) 90
Neratinib (HKI-272; Pfizer) 98
Omnitarg (pertuzumab; Genentech/Roche/Chugai) 104
Ramucirumab (IMC-1121B; Eli Lilly) 113
Trastuzumab-DM1 (ImmunoGen/Genentech/Roche/Chugai) 119
Votrient (pazopanib; GlaxoSmithKline) 127
6. Market Overview: Ovarian Cancer 135
Definition 135
Current treatment options 140
Target product profile versus current level of attainment 155
7. Pipeline Analysis and Forecasts: Ovarian Cancer 157
Abagovomab (ACA-125; Menarini/CellControl BioMedical) 162
AMG 386 (Amgen) 168
Avastin (bevacizumab; Genentech/Roche/Chugai) 174
Farletuzumab (MORAb-003; Morphotek/Eisai) 186
Karenitecin (cositecan; BNP-1350; BioNumerik) 193
Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 199
Vargatef (intedanib/BIBF-1120; Boehringer Ingelheim) 205
Votrient (pazopanib; GlaxoSmithKline) 210
Olaparib (AZD2281; AstraZeneca) 218
8. Market Overview Cervical Cancer 222
Disease definition 222
Patient segmentation 223
Current treatment options 227
Target product profile versus current level of attainment 234
Bibliography 236
Chapter 1: Pipeline Overview and Dynamics 236
Chapter 2: R&D approach 236
Chapter 3: Epidemiology 237
Chapter 4: Market Overview: Breast Cancer 239
Chapter 5: Pipeline Analysis & Forecasts: Breast Cancer 243
Chapter 6: Market Overview: Ovarian Cancer 246
Chapter 7: Pipeline Analysis and Forecasts: Ovarian Cancer 251
Chapter 8: Market Overview: Cervical Cancer 254
Appendix 258
Abbreviations 258
Methodology 258
About Datamonitor 264
Datamonitor consulting 265
Disclaimer 265
To order this report:
: Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker